FindTrial
Sign In

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-000376-14-IT
Enrollment
660
Registered
2005-04-14
Start date
2004-05-28
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MONOTHERAPY TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MedDRA version: 6.1 Level: PT Classification code 10012601

Interventions

Product Code: LAF 237 Pharmaceutical Form: Tablet Current Sponsor code: LAF 237 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Product Name: metformin Pharmac

Sponsors

NOVARTIS FARMA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026